ADRB3 and neuroblastoma: These first results show that β3-AR blockade exerted a significant anti-tumoral activity in a syngeneic model of NB-bearing mice, and that the concomitant administration of PD-L1 antibody did not induce an anti-tumoral synergistic effect.